Screener
Immunome IMNM Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 59,331 | 47,562 |
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
| Net loss per share, basic and diluted | $(0.48) | $(0.52) |
| Weighted-average shares outstanding, basic and diluted | 113,136,836 | 79,410,354 |
| Comprehensive loss: | ||
| Net loss | $(53,839) | $(41,640) |
Item 1. Financial Statements.
FAQ
- What is Immunome's net income?
- Immunome (IMNM) reported net income of -$53.84M in Q1 2026.
- How has Immunome's net income changed year-over-year?
- Immunome's net income decreased by 29.3% year-over-year, from -$41.64M to -$53.84M.
- What is the long-term trend for Immunome's net income?
- Over 4 years (2021 to 2025), Immunome's net income has grown at a 71.2% compound annual growth rate (CAGR), from -$24.71M to -$212.39M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Immunome's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude